Telix Pharmaceuticals Limited dina iki ngumumake yen pasien pisanan wis diwenehi dosis ing studi 'STARLITE 2' Tahap II babagan terapi kanker ginjal investigasi Perusahaan, TLX250 (177Lu-DOTA-girentuximab), ing Memorial Sloan Kettering Cancer Center (MSK) ing New York .

STARLITE 2 (NCT05239533) bakal netepake khasiat radiasi sing ditargetake TLX250 kanthi kombinasi karo imunoterapi kanggo karsinoma sel ginjel sel sing jelas (ccRCC), bentuk kanker ginjel sing paling umum lan agresif. TLX250 target carbonic anhydrase IX (CA9), [1] protein sing banget dituduhake ing pasien sing kamungkinan kanggo nduduhake respon sing luwih winates kanggo imunoterapi kanker.[2] Konsep kasebut yaiku dosis radiasi sing ditargetake bisa ngatasi resistensi kekebalan - utawa "imun prime" tumor lan mulane nggawe luwih responsif marang imunoterapi kanker.

Sinau Tahap II iki, ing pasien sing wis maju sawise immunotherapy sadurunge, bakal ngevaluasi radiasi sing dikirimake TLX250 kanthi kombinasi karo immunotherapy anti-PD-1[3] Opdivo®[4] (nivolumab). Titik pungkasan utamane yaiku kanggo nemtokake safety lan khasiat terapi kombinasi karo TLX250 kaya sing ditaksir dening tumor sing nanggapi terapi Telix tinimbang standar perawatan saiki mung. Agen pencitraan kanca investigasi Telix TLX250-CDx (89Zr-DFO-girentuximab) uga bakal digunakake ing sinau kanggo ekspresi CA9. Panaliten sing dipimpin penyidik lengen tunggal samesthine bakal ndhaptar udakara 30 pasien.

Kepala Petugas Medis Telix, Dr. Colin Hayward nyathet, "Integrasi obat nuklir presisi lan onkologi medis ditindakake lan Telix ana ing ngarep gerakan iki kanggo ngembangake produk pribadi lan regimen sing ramah pasien. Kita pengin ngucapake matur nuwun marang Dr. Darren Feldman lan tim klinise, uga pasien sing bakal nyumbang kanggo sinau sing paling anyar iki.

APA sing kudu dijupuk saka ARTIKEL INI:

The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone.
TLX250 targets carbonic anhydrase IX (CA9),[1] a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.
STARLITE 2 (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combination with immunotherapy for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.